Dr. Manuel Hidalgo, Chief, Division of Hematology and Medical Oncology, WDOM, and colleagues have published a paper in Nature Medicine that shows promising responses using a triple combination approach in patients with metastatic pancreatic cancer.
In this international Phase 2a trial (COMBAT), patients with the most common type of metastatic pancreatic cancer – who had not responded to a first-line treatment – were treated with an investigational drug, an immunotherapy drug, and chemotherapy. As compared to results from standard chemotherapy alone, patients showed improved results in terms of whether their tumors shrank or stayed the same in size. Based on these promising results, investigators on the trial look forward to a future Phase 3 clinical trial to achieve further advances.
The Phase 2a COMBAT trial involved investigators from Weill Cornell Medicine and Beth Israel Deaconness Medical Center. Dr. Hidalgo had led the trial at Beth Israel Deaconness in his past role as Chief of the Division of Hematology as well as Clinical Director of the Rosenberg Clinical Cancer Center.